IMIGRAN 6mg price in UAE

Overview

Welcome to Dwaey, specifically on IMIGRAN 6mg Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Sumatriptan (as succinate).
IMIGRAN 6mg is available in the market in concentration 6mg/Syringe and in the form of Injection/Solution for.

GLAXO is the producer of IMIGRAN 6mg and it is imported from UK, The most popular alternatives of IMIGRAN 6mg are listed downward .

Mode Of Action

Sumatriptan is a selective serotonin agonist that acts at 5-HT1 receptors. It causes vasoconstriction of cranial arteries and/or inhibition of neurogenic inflammatory processes in the CNS. A small but significant delay in gastric emptying also occurs.

Indication

Migraine
Cluster headache

Precaution

Conditions predisposing to seizures, presence of coronary risk factors, cardiac arrhythmias, renal or hepatic impairment, elderly, pregnancy, lactation. Lactation: Excreted in breast milk at very low levels; minimize infant to potential exposure by avoiding breastfeeding for 8-12 hours after administration

Side Effects

>10% Injection site reaction (<86%)
Paresthesia (5-14%)
Dizziness (12%)
Warm/hot sensation (11%) 1-10% Chest discomfort/pressure/tightness (2-5%)
Jaw or neck tightness (1-5%)
Diaphoresis (2%)
Burning sensation (7%)
Cold sensation (1%)
Dysphagia
Sore throat (3%)
Malaise (1%)
Abdominal distress (1%) Frequency Not Defined Agitation
Cardiac arrhythmia: V-fib/V-tach (rare)
Dysuria
Eye irritation
Flushing
MI and coronary artery vasospasm in patients with CAD risk factors (extremely rare)
Nasal discomfort
Palpitations
Tingling
Weakness Potentially Fatal: Cardiac arrhythmias
MI.

Contra indication

Not to be used prophylactically and in patients with basilar or hemiplegic or ophthalmoplegic migraine. History of MI or stroke, severe hepatic impairment, ischaemic heart disease, uncontrolled hypertension, peripheral vascular disease, hypersensitivity to sulfonamides.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Concurrent use increased risk of vasospastic reaction with ergotamine and related compounds. Potentially Fatal: Increased risk of serotonin syndrome with concurrent use of SSRI, MAOIs or within 14 days of stopping MAOIs. Admin of ergotamine or related compounds within the previous 24 hr.